The Rise of the Triple Agonist

A comparative analysis of the metabolic revolution. From Semaglutide's breakthrough to Tirzepatide's dual action, and the investigational power of Retatrutide.

GLP-1 GIP Glucagon

The Contenders

Three generations of incretin-based therapies. While Semaglutide and Tirzepatide are established standards of care, Retatrutide pushes the biological envelope as an investigational triple agonist.

Semaglutide

Standard

Wegovy / Ozempic

Target GLP-1 Only
Max Weight Loss ~15% (STEP-1 Trial)

Tirzepatide

Advanced

Zepbound / Mounjaro

Target GLP-1 + GIP
Max Weight Loss ~21% (SURMOUNT-1 Trial)
PHASE 3

Retatrutide

Next Gen

Investigational (LY3437943)

Target GLP-1 + GIP + Glucagon
Max Weight Loss ~24% (Phase 2 Data)

Mechanism: Triple Agonism

While Semaglutide acts solely on the satiety centers (GLP-1), and Tirzepatide adds GIP for enhanced insulin secretion and lipid buffering, Retatrutide introduces Glucagon receptor agonism.

Why Glucagon? Paradoxically, while glucagon raises blood sugar, in this specific ratio it drives energy expenditure (burning calories) and mobilizes liver fat, while the GLP-1/GIP components keep glucose in check.

Receptor Synergy

  • GLP-1: Satiety & Insulin Secretion
  • GIP: Fat Metabolism & Potency Boost
  • GCGR (Glucagon): Energy Expenditure & Liver Fat
Semaglutide
GLP-1
GIP
GCGR
Tirzepatide
GLP-1
GIP
GCGR
Retatrutide
GLP-1
GIP
GCGR

Efficacy: Breaking Ceilings

Comparative data from pivotal trials (STEP-1, SURMOUNT-1, Retatrutide Ph2). Retatrutide demonstrates the potential to approach bariatric surgery levels of weight loss (>25%).

Mean Body Weight Reduction (%)

At maximum tolerated dose (Source: NEJM Publications)

High-Tier Responders (>15% Loss)

Percentage of participants achieving >15% body weight loss

The "Steatosis" Breakthrough

A unique feature of Retatrutide's glucagon activity is its profound effect on liver fat. In Phase 2 trials, participants on the highest dose saw an average >80% reduction in liver fat, with many achieving complete resolution of steatosis. This positions it as a prime candidate for MASH/NASH treatment.

>80%
Liver Fat Reduction
Retatrutide 12mg

Safety & Tolerability

While gastrointestinal side effects are a class effect, triple agonism introduces specific signals that require monitoring, particularly regarding heart rate and cutaneous sensation.

Common Adverse Events (Titration Phase)

❤️

Heart Rate Signal

Retatrutide trials showed a dose-dependent increase in resting heart rate (peaking at ~5-10 bpm increase). This is likely mediated by the Glucagon receptor. While it tended to decline over time, long-term CV safety data is critical.

⚡

Skin Sensitivity

"Cutaneous Hyperesthesia" (skin tenderness/burning) was reported by ~7% of patients on higher doses of Retatrutide. This is a unique side effect not typically seen with Semaglutide or Tirzepatide.

Regulatory Roadmap

The path from discovery to pharmacy shelves.

June 2021

Semaglutide 2.4mg (Wegovy) Approved

FDA approves the first weekly GLP-1 specifically for chronic weight management.

May 2022

Tirzepatide (Mounjaro) Approved

FDA approves first dual GIP/GLP-1 agonist for Type 2 Diabetes.

June 2023

Retatrutide Phase 2 Published

NEJM publishes results showing up to 24.2% weight loss, sparking global interest.

Nov 2023

Tirzepatide (Zepbound) Approved

FDA approves Tirzepatide specifically for obesity.

Est. 2026-2027

Retatrutide Approval?

Pending successful completion of Phase 3 (TRIUMPH) trials and regulatory review.